Table 5.
Comparison of findings on costs of PD in selected studies.
| Author | Country/Region | Year | n | Design | Costs studied | Perspective | Value/year US$ |
Comments |
|---|---|---|---|---|---|---|---|---|
| Yoritaka et al. [40] | Japan | 2016 | 715 | SPO | D | S | 5,828 | Direct cost |
| Martínez-Martin et al., [44] | Spain | 2015 | 174 | PO/BU | D/I | S | 13,720.24/year 4 | Magnitude of disease and quality of life |
| Tamás et al. [39] | Hungary | 2014 | 110 | PE/BU | D/I/OOP | S/CH | 6,831 | Costs of illness and quality of life |
| Kowal et al. [22] | USA | 2013 | 630,000 | PE | D/I | S | 22,800 | Economic load current and projected (by 2050) in the USA |
| Zhao et al. [19] | Singapore | 2013 | 195 | PE/MK/BU | D/I | S | 68,519 (over the lifetime period) | Cost of illness |
| Johnson et al. [41] | USA | 2013 | 1,151 | RE | D/I | CS | 43,506 PDINST (cohort) | Cost of illness x several cohorts |
| Bhattacharjee and Sambamoorthi [29] | USA | 2013 | 350 | RE | D/OOP | S | 15,404 | Cost of illness/over expenditure associated with PD |
| Kaltenboeck et al. [23] | USA | 2012 | 25,577 | RE | D | G | 78,042 (ambulatory pac. PD) | Survival rates and costs of patients of health programs |
| Bach et al. [43] | Germany | 2012 | 1,449 | PE | D/I | G | 6.00 (2190) to 12.69 (4631.85) | Cost of illness/drugs/comorbidities |
| Lökk et al. [25] | Sweden | 2012 | 4,163 | PE/RE | D | S | 9,333 | Cost of illness/drugs |
| Johnson et al. [20] | USA | 2011 | 278 | PO | I | S/CH/CS | 569,393 (45 years), 188,590 (55), 35,496 (65), 2,451 (75) (from 40 to 79 years) | Indirect costs |
| Jennum et al. [26] | Denmark | 2011 | 13,400 | RE/PO | D/I | S | 7,763 | Cost of illness |
| Zhao et al. [38] | Singapore | 2011 | 195 | PE/BU | D/I/OOP | S | 10,129 | Cost of illness |
| von Campenhausen et al. [45] | Europe (6 countries) | 2011 | 486 | PE/RE/BU | D/I/OOP | S | 2,968 to 11,124 | Cost of illness |
| Winter et al. [30] | Italy | 2010 | 70 | PO/BU | D/I/OOP | S | 19,574 | Cost of illness/drugs |
| Winter et al. [46] | Germany | 2010 | 145 | PO/PE/BU | D/I/OOP | G | 22,763 | Cost of illness |
| Winter et al. [47] | Germany | 2010 | 145/133 | PE/RE | D/I | S | 21,138 to 35,864 | Cost of illness |
| Winter et al. [32] | Czech Rep. | 2009 | 100 | PE/RE/BU | D/I | S/CH/P | 12,483 | Cost of illness |
| Winter et al. [37] | Russia | 2009 | 100 | PE/PO/BU | D/I | S/CH | 5,935 | Cost of illness |
| Vargas et al. [42] | Brazil | 2008 | 144 | PE/PO/BU | IN | NA | NA | Resource use X incapacity |
| McCrone et al. [33] | UK | 2007 | 175 | PE/RE | D/OOP | CS/P | 19,861 | Cost of illness |
| Leibson et al. [35] | USA | 2006 | 92 | PE/RE | D | NA | Unclear | Cost of illness per groups |
| Ragothaman et al. [36] | India | 2006 | 175 | PE/PO | D | S | 707 | Cost of illness/direct costs |
| Wang et al. [48] | China | 2006 | 190 | PE/RE/BU | D/I | S | 925 | Cost of illness |
| Vossius et al. [31] | Germany/Norway | 2006 | 438 | PE/RE/PO | D | S | 2,389 (Germany), 1,620 (Norway) | Cost of PD drugs |
| Noyes et al. [27] | USA | 2006 | 717 | PE/RE | D/OOP | S/P | 18,528 | Cost of illness/drugs/medicare |
| Cordato et al. [28] | Australia | 2006 | 12 | PE/PO | D/I | S | 5,380 | Cost of illness |
| Huse et al. [24] | USA | 2005 | 20,016 | PE/RE | D | CS | 10,037 | Cost of illness |
| Spottke et al. [34] | Germany | 2005 | 145 | PE/PO | D/I/OOP | S/G/P | 22,723 ± 28,297 | Cost of illness |
| Cubo et al. [21] | Spain | 2005 | 23,417 | RE | Int. | G | NA | Years of life lost |
Notes: SPO = semiprospective; PO = prospective; BU = bottom-up; PE = prevalent, MK = Markov; RE = retrospective; D = direct cost; I = indirect cost; OOP = out-of-pocket; Int. = intangible; S = society; CH = human capital; CS = insurance companies; G = government; NA = not applicable; P = patient; PDINST = patients with PD institutionalized; Medicare = USA health care.